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Background: Axillary lymph node status is an important staging and prognostic factor in breast cancer. This study
aimed to evaluate the efficacy of axilla fine needle aspiration cytology (FNAC) in primary breast cancer without a
palpable node and even without image characteristics of a metastatic node.
Methods: From June 2008 to January 2012, 77 patients met the inclusion criteria of having received a FNAC
procedure during the diagnostic protocol of primary breast cancer with the characteristic of impalpable axilla
nodes, and of having received axillary surgery after that, according to the guidelines. The patients’ characteristics,
clinical-pathological features, pre-operative axillary lymph node FNAC findings, surgical lymph node report, and definite
pathologic staging were reviewed.
Results: The FNAC procedures had a reported sensitivity of 58.82%, specificity of 100%, positive predictive value of
100%, negative predictive value of 72.55%, and accuracy of 80.28%. There were no false positives on FNAC; therefore,
the positive likelihood ratio approached infinity. The negative likelihood ratio was 41.18%. Axillary lymph node FNAC is
feasible in newly diagnosed breast cancer patients to evaluate metastatic lymph nodes even in those without clinical
or ultrasonic evidence of lymphadenopathy.
Conclusions: FNAC can be a routine evaluation for most primary breast cancer patients with benefits in expediting
treatment. For those patients with positive findings of the axilla, sentinel node biopsy can be avoided.
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Axillary lymph node status in the initial staging of newly
diagnosed breast carcinoma is important for prognosis
and assessment of treatment options. Though specific
cortical and hilar echo-morphologic changes have been
shown to be predictive of metastatic lymph nodes [1-3],
tissue proof is the main guide to providing definite sta-
ging. Axillary lymph node dissection (ALND) has been a
standard part of breast cancer treatment, but concerns
have arisen following complications such as lymph-
edema, decreased range of motion in the shoulder, and
paresthesia. Therefore, sentinel lymph node biopsy* Correspondence: darren_chen@cch.org.tw
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reproduction in any medium, provided the or(SLNB) was developed to decrease morbidity and avoid
unnecessary ALND [4,5]. Nevertheless, SLNB is still an inva-
sive, technique-dependent, and time-consuming procedure.
Fine needle aspiration cytology (FNAC) of suspicious
nodes via clinical examination and/or ultrasound has be-
come a popular practice in many breast units. It is per-
formed without anesthesia and is generally well tolerated
by the patient, with fewer complications than needle
core biopsy. In most of the reported series, the focus has
been on patients with a suspicious axillary node identi-
fied by ultrasonography or who had palpable lymph
nodes and then underwent FNAC. This selection may
reduce the bias of the operator-dependent procedure,
but limits the application with regards to primary breast
cancer patients.
In the present study, we performed the procedure re-
gardless of clinical or ultrasonic characteristics. FNACLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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imaging evidence of node metastasis in a highly suspi-
cious breast malignancy. Cytology results were com-
pared with pathology after SLNB or ALND.
The aim of the study was to determine whether axil-
lary lymph node ultrasound-guided FNAC can be a safe,
feasible, time-saving, sensitive, and specific tool to pre-
dict metastatic lymph nodes in primary breast cancer
without palpable axillary lymph nodes or even imaging
characteristics of a metastatic node.
Methods
Since June 2008, axillary lymph node ultrasound and
FNAC have been used routinely along with core needle
biopsy by an experienced breast surgeon (more than
20 years’ experience in breast ultrasound examination)
for all patients highly suspicious of having a malignant
lesion of the breast to evaluate the lymph node metasta-
sis status.
All patients with or without a palpable axillary lymph
node received an axilla echogram followed by FNAC.
The aspirational target was the node over the low axilla
(level I), which is the usual location of the sentinel
lymph node. Sonographic characteristics may be taken
as a reference, but are not essential. We aspirated the
node with evacuation using 22 gauge needles. The speci-
men was fixed to the slide with 95% alcohol and was
reviewed by a pathologist. A positive finding was defined
as the presentation of malignant cells. Regardless of the
aspiration cytology results, the patients underwent axil-
lary surgery according to the guidelines for the definite
histopathology report.
All patients who underwent the technique between
June 2008 and January 2012 and gave their consent were
enrolled into the specific registry database. Of the 161
patients who received axillary lymph node FNAC during
this time, 84 met the exclusion criteria (3 patients
underwent breast tumor core needle biopsy at the same
time, revealing a benign lesion; 16 had non-primary
breast cancer; 24 did not undergo surgical intervention;
and 41 received neo-adjuvant therapy before the oper-
ation) and were excluded; 77 patients were finally in-
cluded in the study.
This study focuses on the group of patients diagnosed
with primary breast cancer followed by lymph node op-
eration; whether SLNB or ALND were chosen depended
on the surgeon’s preference. The exclusion criteria in-
cluded a benign lesion in the biopsy report, non-primary
breast cancer, patients without an operation, and patients
who received neoadjuvant therapy before the operation.
The entire protocol was approved by the Institutional Re-
view Board of the hospital.
The patient’s characteristics, clinicopathological features,
pre-operative axillary lymph node FNAC findings, surgicallymph node report, and definite pathologic staging were
reviewed. To evaluate the efficacy of this diagnostic
tool, sensitivity, specificity, accuracy, positive predict-




All 77 patients were female with a mean age of 53.09 years,
ranging from 27 to 76 years. A unilateral lesion was noted
in the patients, 33 (42.86%) on the right side and 44
(57.14%) on the left. Three (3.9%) patients had lymph
nodes suspicious of metastasis in sonograms. Most pa-
tients presented with an expression of hormone receptor
(52 of 77 patients had ER+, 52 had PR+), but less HER2
gene amplification (25 of 77, 32.47%) (Table 1).
Tumor histopathologic characteristics
Gross tumor size was recorded in the pathology report
of the surgical specimen, with sizes ranging from 10 to
70 mm (mean size, 24.4 mm). Most tumors were staged
as T2 (38 of 77 patients, 49.35%) and T1 (28 of 77,
36.36%) lesions. There were 4 Tis, 6 T3, and 1 T4 lesion
in the pathologic T staging statistics. Of the primary
breast carcinoma types, 72 (93.51%) were ductal, 4
(5.19%) were lobular, and 1 (1.3%) was reported to be a
papillary lesion with ductal carcinoma in situ. In the
tumor grading system, 53.25% patients were grade 2 and
32.47% were grade 3 (Table 1).
Axillary lymph node FNAC findings
The included patients all had primary breast cancer and
had undergone axillary lymph node aspiration cytology
at the same time or right after tumor biopsy. A “posi-
tive” result was defined as the presence of malignant
cells (20 of 77 patients, 25.97%) and a “negative” result
as no malignant cells (51 of 77 patients, 66.23%). Six pa-
tients presented with “borderline” findings inclusive of
atypia and an unsatisfactory specimen that could not be
categorized as positive or negative (Table 2), so those pa-
tients were excluded when calculating the efficacy of the
diagnostic tool.
Lymph node management and characteristics
All patients underwent axillary surgery for the definite
histopathologic report. The method of operation was de-
termined by the surgeon’s experience and preference. As
shown in Table 2, 3 of the 20 patients with a positive
FNAC received SLNB and 17 received ALND. All of the
pathologic reports showed evidence of lymph node me-
tastasis. Of the 51 patients with a negative FNAC result,
46 received SLNB, and 13 had lymph node metastasis.
One of the 5 patients receiving ALND had lymph node
involvement.
Table 1 Patient demographic data
Characteristic Total (n = 77) %
Age, yr
Mean (SD) 53.09 (11.31)
Range 27.16–75.72
Tumor size, cm

























Negative for malignant cells 51 66.23
Atypia 4 5.19
Unsatisfactory specimen 2 2.6
Surgical pathology of LN
Positive 38 49.35
Negative 39 50.65









Table 1 Patient demographic data (Continued)







Not identified 20 25.97
Not available 11 14.29
Cheng et al. World Journal of Surgical Oncology 2013, 11:296 Page 3 of 5
http://www.wjso.com/content/11/1/296Diagnostic tool efficacy
The FNAC procedures with 20 positive and 51 negative
results were compared with the surgical pathology re-
ports, both SLND and ALND, to evaluate the efficacy of
the diagnostic tool. There were 34 positive and 37 nega-
tive lymph nodes in the surgical pathologic reports. In
the statistical analysis, sensitivity was 58.82%, specificity
100%, PPV 100%, and NPV 72.55%; the false-positive
rate (FPR) was 0%, and the false-negative rate (FNR) was
41.18% (Table 3).
Discussion
This study demonstrates the benefits of performing axil-
lary lymph node FNAC, especially in the routine exam-
ination of every primary breast cancer patient. We
focused on the efficacy index of this diagnostic tool to
determine if it improves the detection of metastatic
disease and alters the decision-making for the patient’s
treatment.
Lymph node metastasis status is an important factor
in the prognosis of breast cancer. There are various ways
to determine it. To evaluate the efficacy of a diagnostic
technique, sensitivity, specificity, accuracy, PPV, and
NPV are the important indicators. Physical examination
via axillary lymph node palpation is the basic tool to
evaluate the metastatic lymph node, but it has a low spe-
cificity and low sensitivity of 32% to 68%, with a high
false negative rate of 45% [6-10]. Due to the suboptimal sub-
jective judgment of clinical palpation, imaging assessmentTable 2 Results of fine needle aspiration cytology of
axillary lymph nodes
Fine needle aspiration cytology
Axillary procedure Positive Negative Borderline
SLNB 3 46 4
Lymph node-positive 3 13 3
ALND 17 5 1
Lymph node-positive 17 1 1
NA – – 1
SLNB: Sentinel lymph node biopsy; ALND: Axillary lymph node dissection.
Table 3 Efficacy of the diagnostic tools
Lymph node in surgical pathology
(SLNB or ALND)
Positive Negative
FNAC positive 20 0
FNAC negative 14 37
Sensitivity 58.82%
Specificity 100%
Positive predictive value 100%




SLNB: Sentinel lymph node biopsy; ALND: Axillary lymph node dissection;
FNAC: Fine needle aspiration cytology.
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tomography, magnetic resonance imaging, and nuclear
medicine techniques can visualize the axillary lymph
nodes, but ultrasound is the most advantageous tech-
nique and is the most commonly used to characterize
lymph nodes and detect axillary lymph node metasta-
ses [3,6,7,11]. This broadly favored technique offers a
wide variation in sensitivity, with a range of 30% to
92%, and specificity in the range of 69% to 100% [8,9,12].
Some criteria, including size, morphology, color, and pat-
tern, are used to assess a lymph node via ultrasound [13].
However, it is operator-dependent and lacks technique
standardization. The axillary lymph node pathologic re-
port provides objective and reliable node metastasis infor-
mation. ALND or axillary node clearance has traditionally
been a routine management for pathologic examination
and radical treatment. However, the anatomic disruption
caused by ALND may result in infection, hematoma, ser-
oma, arm morbidity, and nerve injury, which compromise
functionality and quality of life. The risk is significantly
less for SLNB [14], and it has become an alternative
method for patients who have clinically negative axillary
lymph nodes, thereby obviating the need for more exten-
sive surgery. The FNR of SLNB is generally accepted to lie
between 5% and 10% [15]. FNAC has been developed and
performed in many breast units. The procedure is less in-
vasive than SLNB and has fewer complications, and is ap-
plied mostly on patients with suspicious nodes via clinical
examination and/or ultrasound.
This study enrolled 77 patients who had undergone
FNAC procedures performed routinely in cases of pri-
mary breast cancer with clinically negative axillary
lymph nodes. FNAC was performed regardless of ultra-
sound characteristics. Our results demonstrated a sensi-
tivity of 58.82%, specificity of 100%, PPV of 100%, NPV
of 72.55%, and an accuracy of 80.28%. There were no false
positives on FNAC; therefore, the positive likelihood ratioapproached infinity. It should be noted that FNAC, as a
diagnostic tool, provides very high specificity resulting in
the excellent predictive power of a positive result.
A number of prospective studies looking at the role of
ultrasound-guided sampling of axillary lymph nodes in
breast cancer have been published [8,16-18]. Reported
sensitivities and specificities in the literature were 40%
to 87%, and 56% to 100%, respectively [16]. In the previ-
ous study by Marti et al. [17], the axillary FNAC was
86% sensitive, 100% specific, and 91% accurate; PPV was
100% and NPV was 78%. Rattay et al. [16] found that in
FNAC of suspicious nodes to determine nodal involve-
ment, sensitivity was 76%, specificity was 100%, PPV was
100%, and NPV was 48%. Chang et al. [18] reported a
positive lymph node FNAC had a PPV of 98.7%. Hayes
et al. [8] illustrated that FNAC had a sensitivity for axil-
lary involvement of 66.3%, and a specificity, PPV, and
NPV of 98.7%, 98.3%, and 71.8%, respectively. In con-
trast, our results manifested lower sensitivity (58.82%),
identical specificity (100%), and higher PPV (100%) and
NPV (72.55%); moreover, there was an extremely low
FPR (0%) and a low FNR (41.18%).
The main advantage of axillary lymph node FNAC is
the positive result. Once evidence of a malignant cell is
found in a patient who receives the examination, treat-
ment can be expedited. In sparing the SLNB procedure,
the patient proceeds directly to ALND or neoadjuvant
chemotherapy. The advantages include not having to
wait for the definitive pathologic response of the sentinel
node and, for those indicated for neoadjuvant chemo-
therapy, avoiding a second surgery. Low sensitivity and
negative results would not alter the current treatment
guidelines and protocols.
There are limitations and possible further develop-
mental directions in our study. FNAC via ultrasound is
operator-dependent to such an extent that sampling may
vary. A unified protocol should be established. In
addition, the enrolled number of patients was relatively
small, leading to difficulty in evaluating the atypia group.
To combine other diagnostic tools with the design cri-
teria may interfere with sensitivity. In addition, cost data
should be collected to evaluate cost-effectiveness. Fur-
thermore, comparative studies and meta-analyses may
be required to identify adequate sensitivity, accuracy,
and FNR in order to make the tool worthwhile.
Conclusions
Axillary lymph node FNAC is a tool with rapid access
and is an office-based device that can be an attractive al-
ternative in the evaluation of lymph node involvement
in newly diagnosed breast cancer patients. It may be ap-
plied routinely before operation due to its high specifi-
city and PPV, and may play a role in sparing SNLB and
proceeding to ALND or neoadjuvant chemotherapy.
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